Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, finds itself at a critical juncture as it advances its pipeline and expands ...

Beijing biotech Sironax has closed a whopping $200 ... development of its RIPK1 inhibitors as well as to expand its pipeline of drug candidates in other classes. RIPK1 – or receptor-interacting ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Xencor's pipeline, built on its proprietary XmAb technology ... it could transform from a clinical-stage biotech to a commercial-stage company, significantly enhancing its valuation and growth ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...

A new report on the UK’s bioscience sector shows it enjoyed a strong 2017, with international investment fuelling pipelines. The UK has reaffirmed itself as one of Europe’s biotech powerhouses ...

Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference in San Francisco and the Global Biopharma Symposium hosted by Jones ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Evaxion Biotech A/S announced the successful closing ... $10.8 million to advance its AI-Immunology™ powered vaccine pipeline and cover operational costs. The offering was priced at $2.71 ...